- Home
- VALN vs NXP Comparison
VALN vs NXP Comparison
Compare VALN & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALN
- NXP
- Stock Information
- Founded
- VALN 2012
- NXP 1992
- Country
- VALN France
- NXP United States
- Employees
- VALN N/A
- NXP N/A
- Industry
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- NXP Trusts Except Educational Religious and Charitable
- Sector
- VALN Health Care
- NXP Finance
- Exchange
- VALN Nasdaq
- NXP Nasdaq
- Market Cap
- VALN 777.9M
- NXP 741.7M
- IPO Year
- VALN 2021
- NXP N/A
- Fundamental
- Price
- VALN $10.71
- NXP $14.41
- Analyst Decision
- VALN Strong Buy
- NXP
- Analyst Count
- VALN 4
- NXP 0
- Target Price
- VALN $15.75
- NXP N/A
- AVG Volume (30 Days)
- VALN 78.1K
- NXP 70.0K
- Earning Date
- VALN 11-06-2025
- NXP 01-01-0001
- Dividend Yield
- VALN N/A
- NXP 4.04%
- EPS Growth
- VALN N/A
- NXP N/A
- EPS
- VALN N/A
- NXP 0.54
- Revenue
- VALN $230,566,060.00
- NXP N/A
- Revenue This Year
- VALN $15.69
- NXP N/A
- Revenue Next Year
- VALN $22.15
- NXP N/A
- P/E Ratio
- VALN N/A
- NXP $26.81
- Revenue Growth
- VALN 25.47
- NXP N/A
- 52 Week Low
- VALN $3.62
- NXP $12.91
- 52 Week High
- VALN $12.25
- NXP $14.89
- Technical
- Relative Strength Index (RSI)
- VALN 53.86
- NXP 56.39
- Support Level
- VALN $9.70
- NXP $14.36
- Resistance Level
- VALN $12.23
- NXP $14.55
- Average True Range (ATR)
- VALN 0.44
- NXP 0.14
- MACD
- VALN 0.04
- NXP -0.02
- Stochastic Oscillator
- VALN 34.78
- NXP 21.67
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.